ELITech
Objective
Invest in a leading international in-vitro diagnostics company, benefitting from a unique IP portfolio and a consistent market growth, backed by an increasing focus on preventive healthcare in the context of increasing medical spending and an aging population. Significant upside potential through products development in key niches of in-vitro diagnostics (e.g., molecular diagnostics including PCR tests), further internationalization and M&A, as well as development of the company’s processes, in light of this primary transaction in partnership with the ELITech’s founder.
Objective
Invest in a leading international in-vitro diagnostics company, benefitting from a unique IP portfolio and a consistent market growth, backed by an increasing focus on preventive healthcare in the context of increasing medical spending and an aging population. Significant upside potential through products development in key niches of in-vitro diagnostics (e.g., molecular diagnostics including PCR tests), further internationalization and M&A, as well as development of the company’s processes, in light of this primary transaction in partnership with the ELITech’s founder.
ENTRY & EXIT
COUNTRY
SECTOR
EMPLOYEES
EMPLOYEES
OVERVIEW
ELITech is vertically integrated with expertise in research and development, manufacturing and distribution. With seven production/assembly sites in Europe, the US and Brazil, its products are sold globally, with (i) direct distribution in 10 key countries, combined with (ii) an established international network of distributors and strong OEM partnerships.
OVERVIEW
It is the only company in the market with a vertically integrated manufacturing process including design, extrusion of aluminum, painting, coating, cutting and assembly all on one site. This business model is replicated in each production hub to achieve higher margins, better inventory management and first-class customer service (e.g., shorter delivery times, high availability).
Key Indicators
2
Key Indicators
∼€10m
R&D per annum
90%
2/span>
To enable ELITech reach its full potential, we focused on:
In parallel, we simplified the organization and reporting structure and helped recruiting new managers to complete the talent pool.
Finally, we assisted the transition from the founder to an independent manager, attracting Siemens’ Head of Molecular Diagnostics and Microbiology business unit as CEO.
Together with management, we streamlined the business model around three key segments, with a special focus on molecular diagnostics, the fastest growing segment of IVD.
In parallel, the company expanded internationally and leveraged its resources through partnerships with large groups.
Finally, we assisted management with two add-on acquisitions, one in France (global leader in mycoplasma diagnostics) and one in the US (manufacturer and distributor of IVD equipment and reagents focusing on clinical chemistry and haematology).
Case Studies